前立腺肥大症に伴う排尿障害に対するテラゾシンとタムスロシンの有効性と安全性の比較

Abstract

排尿障害を有する38例中21例に塩酸テラゾシン(TE)を, 17例に塩酸タムスロシン(TA)を投与し, 両薬剤の有効性と安全性を検討した.国際前立腺症状スコアで評価した自覚症状はTE投与群・TA投与群とも有意に改善した.最大尿流率や平均尿流率等の他覚症状はTE群で有意に改善したのに対しTA群では改善がみられなかった.高血圧・高脂血症を合併する患者においてTEは降圧及びコレステロール低下作用を示した.安全性についてはTE群・TA群とも高く, 未知の副作用は認めなかった.これらの結果から, TEは高血圧・高脂血症を合併する患者や他覚症状の強い患者に対して, TAは服用コンプライアンスに不安のある患者, 他覚症状は強くないが自覚症状の強い患者等に対して用いるのが妥当と考えられた

Terazosin (TE) and tamsulosin (TA) were allocated randomly to 38 patients who had urinary disturbance accompanying prostatic hypertrophy, and the efficacy and safety of the drugs were examined. Subjective symptoms due to I-PSS were improved significantly in both TE and TA groups. On the other hand, objective symptoms such as the maximum urinary flow and mean urinary flow were improved more in the TE group. TE showed hypotensive and cholesterol-decreasing effects in patients who also had hypertension and hyperlipemia. No unknown adverse reactions were observed in either groups, and the drugs were shown to be highly safe. TE was considered to be useful as the first choice drug for the patients with hypertension and or hyperlipemia and those with severe objective symptoms. TA was considered to be useful for the patients with impaired drug compliance or those with severe subjective symptoms though objective symptoms were not so severe.